Systemic and adjuvant therapy for patients with pancreatic carcinoma

Cancer

Volumn 78, Issue 3 SUPPL., 1996, Pages 688-693

  Clark, Jeffrey W ^a,d   Glicksman, Arvin S ^b   Wanebo, Harold J ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

chemotherapy; combined modality; novel approaches; pancreatic cancer; radiation therapy

Indexed keywords

CAMPTOTHECIN; FLUOROURACIL DERIVATIVE; GEMCITABINE; TAXANE DERIVATIVE; TRIMETREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 0030035871     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<688::AID-CNCR50>3.0.CO;2-R     Document Type: Article

References (60)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. Ca Cancer J Clin 1995;45:8-30.
2. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995;31A:882-7.
3. Ellis P, Cunningham D. Management of carcinomas of the upper gastrointestinal tract. Br Med J 1994;308:834-8.
4. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-10.
5. Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995;169:71-8.
6. Johnstone PA, Sindelar WF. Lymph node involvement and pancreatic resection: correlation with prognosis and local disease control in a clinical trial. Pancreas 1993;8:535-9.
7. Rich TA, Evans DB, Curley SA, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol 1994;5(S3):75-80.
8. Garton GR, Gunderson LL, Nagorney DM, Donahue JH, Martin JK, Mcllrath DC, et al. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1993; 27:1153-7.
9. Wagener DJ, Punt CJ, Wilke H. Current status and future directions in the perioperative treatment of pancreatic cancer. Ann Oncol 1994;5(S3):87-90.
10. Weese JL, Nussbaum ML, Paul AR, Engstrom PF, Solin LJ, Kowalyshyn MJ, et al. Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. Int J Pancreatol 1990;7:177-85.
11. Coia L, Hoffman J, Scher R, Weese J, Solin L, Wiener L, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994;30:161-7.
12. Gunderson LL, Nagorney DM, Martenson JA, Donahue JH, Gorton GR, Nelson H, et al. External beam plus intra-operative irradiation for gastrointestinal cancers. World J Surg 1995;19:191-7.
13. 13a. Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 1994;168:361-4.
14. 13b.Whittington R, Dobelbower RR, Mohiuddin M, Rosato FE, Weiss SM. Radiotherapy of unresectable pancreatic carcinoma: a six year experience with 104 patients. Int J Radiat Oncol Biol Phys 1981;7:1639-44.
15. Shipley WU, Nardi GL, Cohen AM, Ling CC. Iodine 125 implant and external beam irradiation in patients with localized pancreatic carcinoma. A comparative study of surgical resection. Cancer 1980;45:709-14.
16. Wagener DJ, deMulder PH, Wils JA. Multimodality treatment of locally advanced pancreatic cancer. Ann Oncol 1994;5(Suppl 3):81-6.
17. Mohiuddin M, Rosato F, Schuricht A, Barbot D, Biermann W, Cantor R. Carcinoma of the pancreas - the Jefferson experience 1975-1988. Eur J Surg Oncol 1994;20:13-20.
18. Earle JD, Foley JF, Wieand HS, Kvols LK, McKenna PJ, Krool JE, et al. Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 1994;28:207-11.
19. Douglass HO. Current approaches to multimodality management of advanced pancreatic cancer. Hepatogastroenterology 1993;40:433-42.
20. Moertel CG, Frytak S, Hahn RG, O'Conell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma. A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. Cancer 1981;48:1705-10.
21. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas. Comparison of combined modality therapy (chemotherapy and radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-5.
22. Klaassen DS, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas. A randomised comparison of 5-FU alone with 5-FU plus concurrent radiotherapy and maintenance 5-FU. An Eastern Cooperative Group study. J Clin Oncol 1985;3:373-8.
23. Taguchi T. Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet 1994;26:275-9.
24. Shimamura Y, Gunven P, Ishii M, Ono M, Abe K. Temporary redistribution of hepatic or pancreatic blood flow by vascular occluders during intra-arterial chemotherapy for carcinoma of the liver or pancreas. Surg Gynecol Obstet 1993;177:617-9.
25. Arredondo MA, Chaudhuri B, Kar R, Grist KA, Thomford NR, Chaudhuri PK. Pharmacokinetics and toxicity of isolated perfusion of human pancreas-duodenum with mitomycin-C. Reg Cancer Treat 1991;3:305-7.
26. Wils JA, Kok T, Wagener DJTh, Selleslag J, Duez N. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993;29A:203-4.
27. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In: DeVita VT Jr., Hellman S, Rosenberg SA editors. Cancer Principles and Practice of Oncology. 4th ed. Philadelphia: J.B. Lippincott Co., 1993:849-82.
28. Moore M, Anderson J, Burris H. A randomized trial of gemcitabine (gem) versus 5FU as first-line therapy in advanced pancreatic cancer [abstract]. Proc ASCO 1995; 14:473.
29. Moertel CG, Rubin J, O'Connell MJ, Schutt AS, Wieand HC. A phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of upper gastrointestinal adenocarcinomas. J Clin Oncol 1986;4:1053-7.
30. Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol 1986;4:1794-8.
31. Moore MJ, Erlichman C, Kaizer L, Fine S. A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer. Anticancer Drugs 1993;4:555-7.
32. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993;60:245-64.
33. Ebert M, Friess H, Beger HG, Buchler MW. Role of octreotide in the treatment of pancreatic cancer. Digestion 1994; 55(S1):48-51.
34. Andrew-Sandberg A. Treatment with an LHRH analogue in patients with advanced pancreatic cancer. Acta Chir Scand 1990;156:549-51.
35. Wong A, Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. Cancer 1993;71:2200-3.
36. Keating JJ, Johnson PJ, Cochrane AMG, Grazzard BG, Krasner N, Smith PM. A prospective randomised controlled trial of tamoxifen and cyproteone acetate in pancreatic carcinoma. Br J Cancer 1989;60:789-92.
37. Klijn JGM, Hoff AM, Plantig AST, Verweij J, Kok T, Lamberts SW, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990;62:627-30.
38. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD, et al. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer. Biologic and clinical effects. J Clin Oncol 1990;8:2019-26.
39. 90Y.B72.3 against pancreatic cancer: dosimetric and biologic analysis. Int J Radiat Oncol Biol Phys 1990;19:627-31.
40. Buchler M, Friess H, Schultheiss HK, Gebhardt C, Kubel R, Muhrer KH, et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991;68:1507-12.
41. Weiner LM, Harvey E, Padavic-Shaller K, Willson JK, Walsh C, Lacreta F, et al. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. J Immunother 1993;13:110-6.
42. Rinaldi DA, Burris HA, Dorr FA, Woodworth JG, Kuhn JR, Eckardt JR, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-50.
43. Casper ES, Green MR, Kelsen DP, Heden RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12:29-34.
44. Rougier Ph, De Forni M, Adenis A, Ducreux M, Djazouli K, Adams D, et al. Phase II study of taxotere (RP56976, doocetaxel) in pancreatic adenocarcinoma (PAC) [abstract]. Proc ASCO 1994;13:587.
45. Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P. Buitenhuis M, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995;6:129-32.
46. Verweij J, Lund B, Beijnen J, Planting A, de Boer-Dennert M, Koier I, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-8.
47. Harrap KA. Initiatives with platinum- and quinazoline-based antitumor molecules: Fourteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995;55:2761-8.
48. Cornelison TL, Goldberg JM, Piver MS. Taxol and platinum chemotherapy in the treatment of pancreatic and jejunal carcinoma. J Surg Oncol 1995;59:204-8.
49. Scarpa A, Capelli P, Villaneuva A, Zaniboni G, Lluis F, Accolla R, et al. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences, Int J Cancer 1994;57:167-71.
50. Pellegata NS, Sessa F, Renault B, Bonato M, Leone B, Solcia E, et al. Ki-ras and p53 mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54:1556-60.
51. Tabata T, Fujimori T, Maeda S, Yamamoto M, Saitoh, The role of Ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis, Int J Pancreatol 1993; 14:237-44.
52. Urban T, Ricci S, Grange JD, Lacave R, Boudghere F, Brietmayer F, et al. Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993;85:2008-12.
53. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142:1534-43.
54. Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor state. Cancer Res 1993;53:5289-96.
55. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, Beger HG, et al. Overexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13:565-9.
56. Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Kerc M. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 1993; 53:4741-4.
57. Dougall WC, Qian X, Greene MI. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J Cell Biochem 1993; 53:61-73.
58. Pals ST, Koopman G, Heider KH, Griffioen A, Adolf GR, Van den Berg T, et al. CD44 splice variants: expression during lymphocyte activation and tumor progression. Behring Inst Mitt 1993;92:273-7.
59. Magarian-Blander J, Domenech N, Finn OJ. Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA. Ann NY Acad Sci 1993;690:231-43.
60. Mason W, Malkin M, Lieberman F, Cropp G, Hannah A. Pharmacokinetics of SU101, a novel signal transduction inhibitor, in patients with recurrent glioma. Proc AACR 1996;37:166.